AEF0217 is being developed as the first treatment for cognitive deficits caused by a hyperactivity of the CB1 receptor, the first indication being those linked to Down syndrome (Trisomy 21), which
Investegate announcements from Step Pharma, Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the 64th American Society of Hematology Annual Meeting
Lyon, Paris, France - 20th October 2022 - 6 pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates
Pier Vincenzo Piazza has won in the "Scale-Up" category for France's Nouvelle Aquitaine region Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage
Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today